These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 35235653)

  • 1. Factors Associated With Systemic Immune Activation Indices in a Global Primary Cardiovascular Disease Prevention Cohort of People With Human Immunodeficiency Virus on Antiretroviral Therapy.
    Looby SE; Kantor A; Burdo TH; Currier JS; Fichtenbaum CJ; Overton ET; Aberg JA; Malvestutto CD; Bloomfield GS; Erlandson KM; Cespedes M; Kallas EG; Masiá M; Thornton AC; Smith MD; Flynn JM; Kileel EM; Fulda E; Fitch KV; Lu MT; Douglas PS; Grinspoon SK; Ribaudo HJ; Zanni MV
    Clin Infect Dis; 2022 Oct; 75(8):1324-1333. PubMed ID: 35235653
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessment of Coronary Artery Disease With Computed Tomography Angiography and Inflammatory and Immune Activation Biomarkers Among Adults With HIV Eligible for Primary Cardiovascular Prevention.
    Hoffmann U; Lu MT; Foldyna B; Zanni MV; Karady J; Taron J; Zhai BK; Burdo T; Fitch KV; Kileel EM; Williams K; Fichtenbaum CJ; Overton ET; Malvestutto C; Aberg J; Currier J; Sponseller CA; Melbourne K; Floris-Moore M; Van Dam C; Keefer MC; Koletar SL; Douglas PS; Ribaudo H; Mayrhofer T; Grinspoon SK;
    JAMA Netw Open; 2021 Jun; 4(6):e2114923. PubMed ID: 34185068
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rationale and design of the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE).
    Grinspoon SK; Fitch KV; Overton ET; Fichtenbaum CJ; Zanni MV; Aberg JA; Malvestutto C; Lu MT; Currier JS; Sponseller CA; Waclawiw M; Alston-Smith B; Cooper-Arnold K; Klingman KL; Desvigne-Nickens P; Hoffmann U; Ribaudo HJ; Douglas PS;
    Am Heart J; 2019 Jun; 212():23-35. PubMed ID: 30928825
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Leveraging a Landmark Trial of Primary Cardiovascular Disease Prevention in Human Immunodeficiency Virus: Introduction From the REPRIEVE Coprincipal Investigators.
    Grinspoon SK; Douglas PS; Hoffmann U; Ribaudo HJ
    J Infect Dis; 2020 Jul; 222(Suppl 1):S1-S7. PubMed ID: 32645161
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of Pitavastatin on Coronary Artery Disease and Inflammatory Biomarkers in HIV: Mechanistic Substudy of the REPRIEVE Randomized Clinical Trial.
    Lu MT; Ribaudo H; Foldyna B; Zanni MV; Mayrhofer T; Karady J; Taron J; Fitch KV; McCallum S; Burdo TH; Paradis K; Hedgire SS; Meyersohn NM; DeFilippi C; Malvestutto CD; Sturniolo A; Diggs M; Siminski S; Bloomfield GS; Alston-Smith B; Desvigne-Nickens P; Overton ET; Currier JS; Aberg JA; Fichtenbaum CJ; Hoffmann U; Douglas PS; Grinspoon SK;
    JAMA Cardiol; 2024 Apr; 9(4):323-334. PubMed ID: 38381407
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Switch to raltegravir decreases soluble CD14 in virologically suppressed overweight women: the Women, Integrase and Fat Accumulation Trial.
    Lake JE; McComsey GA; Hulgan T; Wanke CA; Mangili A; Walmsley SL; Stramotas SA; Tracy R; Currier JS
    HIV Med; 2014 Aug; 15(7):431-41. PubMed ID: 24506429
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Statins for primary cardiovascular disease prevention among people with HIV: emergent directions.
    Fitch KV; Fulda ES; Grinspoon SK
    Curr Opin HIV AIDS; 2022 Sep; 17(5):293-300. PubMed ID: 35938463
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rationale and design of the Mechanistic Substudy of the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE): Effects of pitavastatin on coronary artery disease and inflammatory biomarkers.
    Hoffmann U; Lu MT; Olalere D; Adami EC; Osborne MT; Ivanov A; Aluru JS; Lee S; Arifovic N; Overton ET; Fichtenbaum CJ; Aberg JA; Alston-Smith B; Klingman KL; Waclawiw M; Burdo TH; Williams KC; Zanni MV; Desvigne-Nickens P; Cooper-Arnold K; Fitch KV; Ribaudo H; Douglas PS; Grinspoon SK;
    Am Heart J; 2019 Jun; 212():1-12. PubMed ID: 30928823
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma CXCL10, sCD163 and sCD14 Levels Have Distinct Associations with Antiretroviral Treatment and Cardiovascular Disease Risk Factors.
    Castley A; Williams L; James I; Guelfi G; Berry C; Nolan D
    PLoS One; 2016; 11(6):e0158169. PubMed ID: 27355513
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trans women have worse cardiovascular biomarker profiles than cisgender men independent of hormone use and HIV serostatus.
    Lake JE; Wang R; Barrett BW; Bowman E; Hyatt AN; Debroy P; Candelario J; Teplin L; Bodnar K; McKay H; Plankey M; Brown TT; Funderburg N; Currier JS
    AIDS; 2022 Nov; 36(13):1801-1809. PubMed ID: 35950945
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytomegalovirus Immunoglobulin G (IgG) Titer and Coronary Artery Disease in People With Human Immunodeficiency Virus (HIV).
    Schnittman SR; Lu MT; Mayrhofer T; Burdo TH; Fitch KV; McCallum S; Fulda ES; Zanni MV; Foldyna B; Malvestutto C; Fichtenbaum CJ; Aberg JA; Bloomfield GS; Overton ET; Currier J; Tebas P; Sha BE; Ribaudo HJ; Flynn JM; Douglas PS; Erlandson KM; Grinspoon SK
    Clin Infect Dis; 2023 Feb; 76(3):e613-e621. PubMed ID: 35975297
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sex Differences in Subclinical Atherosclerosis and Systemic Immune Activation/Inflammation Among People With Human Immunodeficiency Virus in the United States.
    Zanni MV; Foldyna B; McCallum S; Burdo TH; Looby SE; Fitch KV; Fulda ES; Autissier P; Bloomfield GS; Malvestutto CD; Fichtenbaum CJ; Overton ET; Aberg JA; Erlandson KM; Campbell TB; Ellsworth GB; Sheth AN; Taiwo B; Currier JS; Hoffmann U; Lu MT; Douglas PS; Ribaudo HJ; Grinspoon SK
    Clin Infect Dis; 2023 Jan; 76(2):323-334. PubMed ID: 36101518
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patterns of Antiretroviral Therapy Use and Immunologic Profiles at Enrollment in the REPRIEVE Trial.
    Fichtenbaum CJ; Ribaudo HJ; Leon-Cruz J; Overton ET; Zanni MV; Malvestutto CD; Aberg JA; Kileel EM; Fitch KV; Van Schalkwyk M; Kumarasamy N; Martinez E; Santos BR; Joseph Y; Lo J; Siminski S; Melbourne K; Sponseller CA; Desvigne-Nickens P; Bloomfield GS; Currier JS; Hoffmann U; Douglas PS; Grinspoon SK;
    J Infect Dis; 2020 Jul; 222(Suppl 1):S8-S19. PubMed ID: 32645162
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differences in statin utilization and lipid lowering by race, ethnicity, and HIV status in a real-world cohort of persons with human immunodeficiency virus and uninfected persons.
    Riestenberg RA; Furman A; Cowen A; Pawlowksi A; Schneider D; Lewis AA; Kelly S; Taiwo B; Achenbach C; Palella F; Stone NJ; Lloyd-Jones DM; Feinstein MJ
    Am Heart J; 2019 Mar; 209():79-87. PubMed ID: 30685678
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk of Cardiovascular Events in People with HIV (PWH) Treated with Integrase Strand-Transfer Inhibitors: The Debate Is Not Over; Results of the SCOLTA Study.
    Corti N; Menzaghi B; Orofino G; Guastavigna M; Lagi F; Di Biagio A; Taramasso L; De Socio GV; Molteni C; Madeddu G; Salomoni E; Pellicanò GF; Pontali E; Bellagamba R; Celesia BM; Cascio A; Sarchi E; Gulminetti R; Calza L; Maggi P; Cenderello G; Bandera A; Carleo MA; Falasca K; Ferrara S; Martini S; Guadagnino G; Angioni G; Bargiacchi O; Ricci ED; Squillace N; Bonfanti P
    Viruses; 2024 Apr; 16(4):. PubMed ID: 38675955
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of statins beyond lipid-lowering agents in ART-treated HIV infection.
    Mehraj V; Chen J; Routy JP
    Front Immunol; 2024; 15():1339338. PubMed ID: 38655259
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sevelamer does not decrease lipopolysaccharide or soluble CD14 levels but decreases soluble tissue factor, low-density lipoprotein (LDL) cholesterol, and oxidized LDL cholesterol levels in individuals with untreated HIV infection.
    Sandler NG; Zhang X; Bosch RJ; Funderburg NT; Choi AI; Robinson JK; Fine DM; Coombs RW; Jacobson JM; Landay AL; Douek DC; Tressler R; Read SW; Wilson CC; Deeks SG; Lederman MM; Gandhi RT;
    J Infect Dis; 2014 Nov; 210(10):1549-54. PubMed ID: 24864123
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of integrase inhibitors vs protease inhibitors is associated with improved HIV viral suppression.
    Kleinmann WN; Pruszynski JE; Adhikari EH
    Am J Obstet Gynecol MFM; 2023 Nov; 5(11):101151. PubMed ID: 37689245
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Geographical Differences in the Self-Reported Functional Impairment of People With Human Immunodeficiency Virus (HIV) and Associations With Cardiometabolic Risk.
    Erlandson KM; Fitch KV; McCallum SA; Ribaudo HJ; Overton ET; Zanni MV; Bloomfield GS; Brown TT; Fichtenbaum CJ; Bares S; Aberg JA; Douglas PS; Fulda ES; Santana-Bagur JL; Castro JG; Moran LE; Mave V; Supparatpinyo K; Ponatshego PL; Schechter M; Grinspoon SK
    Clin Infect Dis; 2022 Sep; 75(7):1154-1163. PubMed ID: 35165682
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Weight gain among treatment-naïve persons with HIV starting integrase inhibitors compared to non-nucleoside reverse transcriptase inhibitors or protease inhibitors in a large observational cohort in the United States and Canada.
    Bourgi K; Jenkins CA; Rebeiro PF; Palella F; Moore RD; Altoff KN; Gill J; Rabkin CS; Gange SJ; Horberg MA; Margolick J; Li J; Wong C; Willig A; Lima VD; Crane H; Thorne J; Silverberg M; Kirk G; Mathews WC; Sterling TR; Lake J; Koethe JR;
    J Int AIDS Soc; 2020 Apr; 23(4):e25484. PubMed ID: 32294337
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.